HOOKIPA Pharma Revenue 2018-2021 | HOOK

HOOKIPA Pharma revenue from 2018 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
HOOKIPA Pharma Annual Revenue
(Millions of US $)
2020 $20
2019 $12
2018 $8
2017 $
HOOKIPA Pharma Quarterly Revenue
(Millions of US $)
2021-06-30 $5
2021-03-31 $5
2020-12-31 $5
2020-09-30 $4
2020-06-30 $7
2020-03-31 $4
2019-12-31 $4
2019-09-30 $2
2019-06-30 $4
2019-03-31 $2
2018-12-31 $5
2018-09-30 $2
2018-06-30 $1
2018-03-31
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.161B $0.020B
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company. It is engaged in developing a class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform which is designed to reprogram the body's immune system. HOOKIPA Pharma Inc. is based in New York, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29